# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

| Name o | of entity   |  |
|--------|---|--|
| Ora    | a Banda Mining Ltd  |  |
| ABN    |   |  |
| 69     | 100 038 266   |  |
| We (t  | he entity) give ASX the following   | information.   |
|        | 1 - All issues ust complete the relevant sections (attach   | sheets if there is not enough space).  |
| 1      | <sup>+</sup> Class of <sup>+</sup> securities issued or to be issued  | Unlisted options (Incentive Options)   |
| 2      | Number of *securities issued or<br>to be issued (if known) or<br>maximum number which may be<br>issued                      | 11,251,358 unlisted options (Incentive Options)  |
| 3      | Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount | 11,251,358 Incentive Options issued under the terms and conditions of the Company's ESOP approved by shareholders on 7 June 2019. The Incentive Options are subject to certain vesting |

+ See chapter 19 for defined terms.

payment;

outstanding and due dates for

securities, the conversion price

and dates for conversion)

+convertible

04/03/2013 Appendix 3B Page 1

holder.

conditions and KPIs specific to each employee

No - unlisted options. On exercise or vesting of Do the +securities rank equally in 4 the options, fully paid ordinary shares issued will all respects from the +issue date rank equally with existing quoted fully paid with an existing +class of quoted ordinary shares currently on issue. \*securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution interest payment Issue price or consideration Nil consideration - issued subject to the terms 5 and conditions of the Company's ESOP approved by Shareholders at the 7 June 2019 General Meeting. 11,251,358 unlisted options issued to certain 6 Purpose of the issue employees of the Company subject to the terms (If issued as consideration for the acquisition of assets, clearly and conditions of the Company's ESOP approved identify those assets) by Shareholders at the 7 June 2019 General Meeting. No 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed

under rule 7.1

Number of \*securities issued

without security holder approval

6c

04/03/2013 Appendix 3B Page 2

Nil

<sup>+</sup> See chapter 19 for defined terms.

| 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)  6f Number of *securities issued under rule 7.2 for Company's ESOP approved by Shareholders at the 7 June 2019 General Meeting – exception 9.  6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.  6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – Tomplete Annexure 1 and release to ASX Market Announcements  6i Value 4 July 2019  6i Value 7.1A – N/A  6i Value 7.1A – N/A | • | ou | with security holder approval under rule 7.1A   | INII  |
|---|---|----|---|---|
| the Company's ESOP approved by Shareholders at the 7 June 2019 General Meeting – exception 9.  6g   | ( | 6e | with security holder approval<br>under rule 7.3, or another<br>specific security holder approval  | Nil   |
| 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.  6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  Listing Rule 7.1 – 72,857,994  Listing Rule 7.1A – N/A  4 July 2019  7 *Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.   | ( | 6f |   | the Company subject to the terms and conditions<br>of the Company's ESOP approved by<br>Shareholders at the 7 June 2019 General Meeting |
| rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  Listing Rule 7.1 – 72,857,994  Listing Rule 7.1A – N/A  Listing Rule 7.1A – N/A  4 July 2019  4 July 2019   | • | 6g | 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP  | N/A   |
| issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  Listing Rule 7.1A – N/A  Listing Rule 7.1A – N/A   *Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.   | ( | 6h | rule 7.1A for non-cash<br>consideration, state date on<br>which valuation of consideration<br>was released to ASX Market  | N/A   |
| Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.   | ( | 6i | issue capacity under rule 7.1 and<br>rule 7.1A – complete Annexure 1<br>and release to ASX Market   |   |
|   |   | 7  | Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. | 4 July 2019   |

<sup>+</sup> See chapter 19 for defined terms.

8 Number and +class of all +securities quoted on ASX (*including* the +securities in section 2 if applicable)

| Number      | <sup>+</sup> Class                      |
|-------------|---|
| 485,719,962 | Fully paid ordinary<br>shares (ASX:OBM) |
|             |   |

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

| Number     | +Class  |
|------------|---|
| 1,468,334  | Unlisted Options<br>exercisable at \$2.835 each<br>on or before 8 March<br>2020     |
| 2,178,331  | Unlisted Options<br>exercisable at \$2.9625<br>each on or before 31<br>January 2023 |
| 2,178,331  | Unlisted Options<br>exercisable at \$3.3375<br>each on or before 31<br>January 2023 |
| 509,500    | Unlisted Options<br>exercisable at \$3.1125 each<br>on or before 2 February<br>2021 |
| 66,667     | Unlisted Options<br>exercisable at \$6.1875<br>each on or before 2<br>February 2021 |
| 3,854,862  | Unlisted Options<br>exercisable at \$2.9625<br>each on or before 2<br>February 2023 |
| 3,854,862  | Unlisted Options<br>exercisable at \$3.3375<br>each on or before 2<br>February 2023 |
| 2,916,667  | Unlisted Options<br>exercisable at \$1.125 each<br>on or before 11 June 2023        |
| 7,666,667  | Unlisted Options<br>exercisable at \$0.2625<br>each on or before 11 June<br>2021    |
| 1,155,001  | Remuneration Options  |
| 16,584,691 | Incentive Options   |
| 2,000,000  | Performance Options   |

<sup>+</sup> See chapter 19 for defined terms.

|        | -  |     |
|--------|--|-----|
| 1      | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)   | N/A |
| Part 2 | 2 - Pro rata issue   |     |
| 11     | Is security holder approval required?  | N/A |
| 12     | Is the issue renounceable or non-renounceable?   |     |
| 13     | Ratio in which the <sup>+</sup> securities will be offered   |     |
| 14     | <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates   |     |
| 15     | <sup>+</sup> Record date to determine entitlements   |     |
| 16     | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?   |     |
| 17     | Policy for deciding entitlements in relation to fractions  |     |
| 18     | Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7. |     |
| 19     | Closing date for receipt of acceptances or renunciations   |     |

<sup>+</sup> See chapter 19 for defined terms.

| 20 | Names of any underwriters   |  |
|----|---|--|
| 21 | Amount of any underwriting fee or commission  |  |
| 22 | Names of any brokers to the issue   |  |
| 23 | Fee or commission payable to the broker to the issue  |  |
| 24 | Amount of any handling fee<br>payable to brokers who lodge<br>acceptances or renunciations on<br>behalf of security holders                                 |  |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting   |  |
| 26 | Date entitlement and acceptance<br>form and offer documents will be<br>sent to persons entitled   |  |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders |  |
| 28 | Date rights trading will begin (if applicable)  |  |
| 29 | Date rights trading will end (if applicable)  |  |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker?  |  |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   |  |

<sup>+</sup> See chapter 19 for defined terms.

| 32      | How do security holders dispose of their entitlements (except by sale through a broker)? |  |
|---------|--|--|
| 33      | <sup>+</sup> Issue date  |  |
|         | 3 - Quotation of securit   |  |
| 34      | Type of *securities (tick one)   |  |
| (a)     | *Securities described in Par   | rt 1   |
| (b)     |  | end of the escrowed period, partly paid securities that become fully paid,<br>hen restriction ends, securities issued on expiry or conversion of convertible |
|         | es that have ticked box 34(a)  |  |
| Tick to | o indicate you are providing the informo<br>ents   | ntion or   |
| 35      |  | y securities, the names of the 20 largest holders of the<br>the number and percentage of additional <sup>+</sup> securities                                  |
| 36      |  | ry securities, a distribution schedule of the additional number of holders in the categories   |
| 37      | A copy of any trust deed fo  | r the additional <sup>+</sup> securities   |

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(b)

| 38 | Number of *securities for which *quotation is sought   |        |        |
|----|--|--------|--------|
| 39 | <sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought  |        |        |
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  |        |        |
|    | <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> |        |        |
| 41 | Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period   |        |        |
|    | (if issued upon conversion of another *security, clearly identify that other *security)  |        |        |
|    |  |        |        |
| 42 | Number and +class of all +securities quoted on ASX (including the +securities in clause 38)  | Number | +Class |

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 5 July 2019

(Director/Company secretary)

Starte

Print name: Susan Hunter

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

| Rule 7.1 – Issues exceeding 15% of capital  |  |  |  |
|---|--|--|--|
| Step 1: Calculate "A", the base fig capacity is calculated  | Step 1: Calculate "A", the base figure from which the placement capacity is calculated   |  |  |
| Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue  | 761,784,738 (Pre-consolidation)  |  |  |
| Add the following:  |  |  |  |
| <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul> | 25/9/2018 – 12 fully paid ordinary shares. (Pre-consolidation)  28/5/2019 – 761,780,013 fully paid ordinary shares. (LR 7.2 Exception 1 and 3) (Pre-consolidation)  11/6/19 - 5,762,236,596 fully paid ordinary shares. (Approved 7 June 2019) (Pre-consolidation) |  |  |
| Subtract the number of fully paid  †ordinary securities cancelled during that  12 month period  | -  |  |  |
| "A"   | 485,719,962<br>(7,285,801,359 pre-consolidation)   |  |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A"  |   |  |
|---|---|--|
| "B"   | 0.15  |  |
|   | [Note: this value cannot be changed]                            |  |
| Multiply "A" by 0.15  | 72,857,994  |  |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used   |   |  |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:  | -   |  |
| Under an exception in rule 7.2  |   |  |
| Under rule 7.1A   |   |  |
| With security holder approval under<br>rule 7.1 or rule 7.4   |   |  |
| <ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |   |  |
| "C"   | -   |  |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1  |   |  |
| "A" x 0.15  | 72,857,994  |  |
| Note: number must be same as shown in Step 2  |   |  |
| Subtract "C"  | -   |  |
| Note: number must be same as shown in Step 3  |   |  |
| <b>Total</b> ["A" x 0.15] – "C"   | 72,857,994  |  |
|   | [Note: this is the remaining placement capacity under rule 7.1] |  |

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

| ment capacity f  | or eligible entities |  |
|--|----------------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated             |                      |  |
| N/A  |                      |  |
|  |                      |  |
|  |                      |  |
| 0.10   |                      |  |
| Note: this value   | cannot be changed    |  |
|  |                      |  |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used |                      |  |
|  |                      |  |
|  |                      |  |
|  |                      |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A |  |  |
|---|--|--|
| "A" x 0.10  |  |  |
| Note: number must be same as shown in Step 2  |  |  |
| Subtract "E"  |  |  |
| Note: number must be same as shown in Step 3  |  |  |
| <b>Total</b> ["A" x 0.10] – "E"   |  |  |
|   | Note: this is the remaining placement capacity under rule 7.1A |  |

<sup>+</sup> See chapter 19 for defined terms.